Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Single-arm, Open-label Study to Assess Efficacy and Safety of LB54640 in Patients With Obesity Due to POMC, PCSK1, or LEPR Deficiency.

NCT06041841 is registered in ClinicalTrials.gov with LG Chem as lead sponsor.

NCT NCT06041841
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06041841 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Single-arm, Open-label Study to Assess Efficacy and Safety of LB54640 in Patients With Obesity Due to POMC, PCSK1, or LEPR Deficiency.
Lead sponsor
LG Chem
Phase
Phase 2
Overall status
Unknown status
Start date
December 31, 2023
Completion date
December 31, 2025
Enrollment
4 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

lepr deficiency obesity, pcsk1 deficiency obesity, pomc deficiency obesity